title: [Efficacy of the use of sirolimus covered stents in the treatment of diffuse atherosclerotic lesions of coronary arteries].
abstract: Aim of the study was to compare efficacy of sirolimus covered (116 patients, group 1) and bare (117 patients, group 2) stents. Groups were comparable according to main characteristics. Proportion of patients with diabetes was 19 and 13.7%, with multivessel lesions--87.1 and 80.4%, with arterial diameter <2.75 mm--46.5 and 23.9% in group 1 and 2, respectively. Lesion length was 25.9+/-6.6 mm (28-93 mm) in group 1 and 22.1+/-7.8 mm (26-102 mm) in group 2. Overall 473 stents were implanted into 232 arteries (2.1 per artery). In group 1 184 stents were implanted in 116 arteries, in group 2--289 stents in 117 arteries. Immediate success rate was 97.4 and 99.1% in groups 1 and 2, respectively (p=0.74). There were no cases of acute stent thrombosis. Subacute thrombosis (after 1-3 weeks) occurred in 2 patients (1.7%) of group 1 and in 1 patient (0.85%) of group 2 (p=0.47). Angiographic restenosis was observed in 12 (10.6%) and 66 (56.9%) patients in groups 1 and 2, respectively (p<0.0025). In 47 of 66 patients (71.2%) in group 2 restenosis was diffuse. There was no case of diffuse restenosis in group 1. Twelve months survival without angina and major coronary events was 79.8% in group 1 and 31%--in group 2.
authors.forename: A M
authors.initials: AM
authors.lastname: Babunashvili
authors.forename: I E
authors.initials: IE
authors.lastname: Iudin
authors.forename: D P
authors.initials: DP
authors.lastname: Dundua
authors.forename: D S
authors.initials: DS
authors.lastname: Kartashov
authors.forename: Z A
authors.initials: ZA
authors.lastname: Kavteladze
mesh_terms: D019917:Blood Vessel Prosthesis Implantation / Q000295:instrumentation*; D020099:Coated Materials, Biocompatible; D017023:Coronary Angiography; D003324:Coronary Artery Disease / Q000000981:diagnostic imaging / Q000601:surgery*; D023903:Coronary Restenosis / Q000517:prevention & control; D005260:Female; D006801:Humans; D007166:Immunosuppressive Agents / Q000494:pharmacology*; D008297:Male; D008875:Middle Aged; D020123:Sirolimus / Q000494:pharmacology*; D015607:Stents; D016896:Treatment Outcome
chemical_list: D020099:Coated Materials, Biocompatible; D007166:Immunosuppressive Agents; D020123:Sirolimus